CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 18 enrolled
Drug / intervention
mutation analysis +5 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01093612
NCT01093612N/AActive
CompareCT.gov

64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer

City of Hope Medical Center·interventional·Posted Mar 26, 2010·Updated Nov 14, 2025

In Brief

A clinical study evaluating positron emission tomography, copper Cu 64-DOTA-trastuzumab, and 4 other interventions for Breast Cancer and Stage IV Breast Cancer. Active but no longer recruiting, targeting 18 participants across 1 site.

Detailed Summary

RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab-labeled positron emission tomography (PET) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--

Timeline

N/AActive
201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2010
Enrollment StartMar 16, 2011
Primary CompletionOct 23, 2018
Study CompletionSep 8, 2026
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 16.3 years ago

Interventions

positron emission tomographyprocedure

PET images performed on a GE Discovery 16 Ste PET-CT scanner

copper Cu 64-DOTA-trastuzumabradiation

15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.

Biopsyprocedure

Correlative Studies

Immunohistochemistry staining methodother

Correlative studies

laboratory biomarker analysisother

Correlative studies

mutation analysisgenetic

Correlative studies